Skip to main content

View full-text article in PMC

. 2013 Mar 26;11(3):259–274. doi: 10.1007/s40258-013-0021-5

Table 8.

Cost-effectiveness results for indacaterol for a 3-year time horizon

	Indacaterol 150 μg	Tiotropium 18 μg	Difference
Total costs	£4534	£4781	−£248
Total QALYs	2.158	2.150	0.008
ICER			Dominant^a
	Indacaterol 150 μg	Salmeterol 2 × 50 μg	Difference
Total costs	£4583	£4692	−£110
Total QALYs	2.158	2.149	0.008
ICER			Dominant^a
	Indacaterol 300 μg	Tiotropium 18 μg	Difference
Total costs	£4501	£4760	−£259
Total QALYs	2.162	2.151	0.011
ICER			Dominant^a

^aDominant = less cost, better outcomes

ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-years